BHVN vs. SMMT, RARE, IDYA, XENE, PBH, AXSM, CORT, HCM, ARWR, and INSM
Should you be buying Biohaven stock or one of its competitors? The main competitors of Biohaven include Summit Therapeutics (SMMT), Ultragenyx Pharmaceutical (RARE), IDEAYA Biosciences (IDYA), Xenon Pharmaceuticals (XENE), Prestige Consumer Healthcare (PBH), Axsome Therapeutics (AXSM), Corcept Therapeutics (CORT), HUTCHMED (HCM), Arrowhead Pharmaceuticals (ARWR), and Insmed (INSM). These companies are all part of the "pharmaceutical preparations" industry.
Biohaven (NYSE:BHVN) and Summit Therapeutics (NASDAQ:SMMT) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership, community ranking and earnings.
Biohaven currently has a consensus price target of $51.63, indicating a potential upside of 39.23%. Summit Therapeutics has a consensus price target of $7.50, indicating a potential upside of 67.04%. Given Summit Therapeutics' higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than Biohaven.
In the previous week, Biohaven had 26 more articles in the media than Summit Therapeutics. MarketBeat recorded 27 mentions for Biohaven and 1 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.40 beat Biohaven's score of 0.18 indicating that Summit Therapeutics is being referred to more favorably in the news media.
Biohaven received 86 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 65.43% of users gave Biohaven an outperform vote while only 57.00% of users gave Summit Therapeutics an outperform vote.
Biohaven has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.13, suggesting that its stock price is 213% less volatile than the S&P 500.
88.8% of Biohaven shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 16.0% of Biohaven shares are owned by company insiders. Comparatively, 83.7% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Biohaven has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.
Summit Therapeutics' return on equity of -125.07% beat Biohaven's return on equity.
Summary
Biohaven beats Summit Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Biohaven News Delivered to You Automatically
Sign up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BHVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biohaven Competitors List
Related Companies and Tools
